Comparison of lenvatinib plus pembrolizumab versus first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a real-world retrospective study

Comparison of lenvatinib plus pembrolizumab versus first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a real-world retrospective study

BackgroundSystemic chemotherapy (SC) stands the only first-line treatment for advanced intrahepatic cholangiocarcinoma (iCCA) for the past few decades. Immune checkpoint inhibitors (ICIs) have been proved to provide additional benefit in disease control. However, oncological outcome of iCCA remains...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhenyun Yang, Weijie Wu, Zhiwen Hu, Yizhen Fu, Zili Hu, Yangxun Pan, Juncheng Wang, Jinbin Chen, Zhongguo Zhou, Yaojun Zhang, Minshan Chen, Dandan Hu
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-11-01
Series:Frontiers in Immunology
Subjects:
intrahepatic cholangiocarcinoma
lenvatinib
pembrolizumab
systemic chemotherapy
survival
adverse events
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1494520/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items